Media coverage about Tabula Rasa Healthcare (NASDAQ:TRHC) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tabula Rasa Healthcare earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4233933048339 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Tabula Rasa HealthCare Subsidiary CareKinesis Receives Board Certified Geriatric Pharmacist Recognition Across All Clinicians (finance.yahoo.com)
- Tabula Rasa Healthcare Inc. (TRHC) Cut to “Market Perform” at Wells Fargo & Company (americanbankingnews.com)
- BRIEF-Tabula Rasa Healthcare paid $35 mln to Sinfonía Healthcare after merger (reuters.com)
- Tabula Rasa Healthcare (TRHC) Presents At 2017 Wells Fargo Healthcare Conference – Slideshow (seekingalpha.com)
- Tabula Rasa HealthCare (TRHC) Reports Acquisition of SinfoniaRx (streetinsider.com)
Tabula Rasa Healthcare (NASDAQ:TRHC) traded up 1.90% during mid-day trading on Tuesday, hitting $22.02. The stock had a trading volume of 158,669 shares. The company’s 50 day moving average price is $17.90 and its 200 day moving average price is $14.79. Tabula Rasa Healthcare has a 52 week low of $10.39 and a 52 week high of $23.80. The firm’s market cap is $380.64 million.
Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its quarterly earnings data on Monday, August 7th. The company reported $0.06 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.06. The company had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. Tabula Rasa Healthcare had a negative return on equity of 9.58% and a negative net margin of 10.27%. Tabula Rasa Healthcare’s quarterly revenue was up 32.6% on a year-over-year basis. Analysts anticipate that Tabula Rasa Healthcare will post $0.41 earnings per share for the current year.
Several research analysts have commented on TRHC shares. Zacks Investment Research raised Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. Chardan Capital boosted their price target on Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and set a $16.00 price target on shares of Tabula Rasa Healthcare in a report on Friday, July 14th. Wells Fargo & Company cut Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $17.00 to $21.00 in a report on Thursday, September 7th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $20.00 price target (up from $19.00) on shares of Tabula Rasa Healthcare in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Tabula Rasa Healthcare currently has a consensus rating of “Buy” and a consensus target price of $19.43.
WARNING: “Tabula Rasa Healthcare (TRHC) Earns Media Impact Rating of 0.17” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/09/12/tabula-rasa-healthcare-trhc-earns-media-impact-rating-of-0-17.html.
In related news, CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $17.21, for a total transaction of $137,680.00. Following the transaction, the chief executive officer now directly owns 918,362 shares of the company’s stock, valued at approximately $15,805,010.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 24,000 shares of company stock worth $363,440. 45.80% of the stock is currently owned by insiders.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.